Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
130
resultados
Última actualización
06/12/2025 [07:00:00]
Resumen de: WO2025249486A1
Provided are a program, a system, an information processing device, a server, and a method capable of executing a game in which a game effect occurs on the basis of continuously measured biological information. There is provided a program to be executed by a computer including a processor and a memory, the program causing the processor to execute a step of acquiring continuous blood glucose level data of a user associated with time information including an acquisition time prior to an acquisition time point, and a step of generating a predetermined game effect on the basis of the continuous blood glucose level data within a predetermined time period.
Resumen de: WO2025245624A1
It is provided an insulin formulation comprising insulin and antimicrobial excipients for use in insulin pumps, connected to subcutaneous tissue via a catheter, a method also known as continuous subcutaneous insulin infusion, wherein the antimicrobial excipient inhibits growth of bacteria in insulin formulations and biofilm bacterial population formation on the internal surfaces of a catheter, allowing extending the time of use of the catheter.
Resumen de: WO2025247647A1
The invention provides an apparatus for non-invasive in vivo measurement by Raman spectroscopy of analyte presence and/or concentration, such as glucose, in the skin of a subject, the apparatus comprising; a planar probe having one or more optical sources for irradiating a sample such as the skin of a subject; a spectrometer configured to receive Raman scattered radiation collected from the sample in response to the received radiation from the one or more optical sources; a numerical aperture controller to determine the numerical aperture of the apparatus, and thereby control the input light received by the spectrometer.
Resumen de: US2025372257A1
Methods, systems, and apparatuses for modeling and determining of an insulin elimination rate in individuals are described. One or more physiological measurements associated with an individual may be determined and applied to a multi-compartment model. One or more physiological parameters, including an insulin elimination rate, may be determined based on applying the one or more physiological measurements to the multi-compartment model.
Resumen de: AU2025267469A1
22222883_1 (GHMatters) P120626.AU.1 In some aspects, a system is provided for gathering and processing sensor data to identify a risk of impacting or causing a venous leg ulcer, wherein the system includes computer- readable memory and one or more processors and is configured to: obtain sensor feature data including a set of feature data representing output of a user sensor configured to be worn on a limb of a user; determine an activity classification using the set of feature data and an activity classification model, wherein the activity classification model includes a decision tree configured to assign the set of feature data to one of a plurality of different activity classifications wherein the different activity classifications comprises: i a first activity classification representing motion of the limb; ii a second activity classification representing no motion of the limb with static weight such as standing; and iii a third activity classification representing that the user is lying down; wherein the system is further configured to generate display data representing the activity classification; and transmit the display data to a computing device configured to present the display data. ov o v
Resumen de: EP4656125A1
One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.
Resumen de: EP4657457A1
One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved.
Resumen de: EP4656133A2
The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: GB2641380A
An apparatus 2 for non-invasive in vivo measurement by Raman spectroscopy of analyte presence and/or concentration, such as glucose, in the skin of a subject is provided. The apparatus comprises a planar probe 8 having one or more optical sources (151, Fig. 1C) for irradiating a sample; a spectrometer 4 configured to receive Raman scattered radiation collected from the sample; a numerical aperture controller to determine the numerical aperture of the apparatus, and thereby control the input light received by the spectrometer. The numerical aperture controller may comprise an aperture stop (14, Fig 2A) within the spectrometer. The numerical aperture controller may be part of the probe for example a light absorbing region (25, Fig. 2C) around an opening in the PCB layer for receiving a Raman signal. Alternatively, the numerical aperture of an optical fibre interface (36, Fig. 5C) or buried light guide (54, Fig. 6B) may be selected; or the combination of a micro lens array (68, Fig. 7A) and pinhole array (64, Fig. 7B) in the probe may be selected to determine the numerical aperture.
Resumen de: EP4657456A2
Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
Resumen de: EP4656127A2
The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.
Resumen de: NZ803295A
Prior art glucose measurement devices have issues relating to poor user experiences where manual multiple steps are required to obtain readings. Herein described is a glucose measurement apparatus, comprising a plunger body (300) disposed inside the main case and configured to move the body attachable unit from a first location to a second location, a needle unit (550) separably coupled to the body attachable unit, a return prevention unit (340, 161) configured to block returning movement of the plunger body to the first position after the plunger body is moved to the second position is included in the main case, and the needle unit (550) is configured to move together with the body attachable unitas the body attachable unit being moved from the first location to the second location, and is configured to move toward the first location after the body attachable unit is inserted into the body.
Resumen de: US2025364143A1
A method for determination of an event-related index for a human user, where:one provides time-based data for an observation period, with:time-based blood glucose data for the totality of the observation period, said time-based blood glucose data being derived from a continuous glucose monitor,time-based event data for the event period,a computerized index determination module determines said event-related index as a composite index of the blood glucose data related to the event period and the blood glucose data outside the event period.
Resumen de: US2025359790A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Resumen de: US2025360273A1
An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.
Resumen de: US2025359828A1
The technologies discussed herein relate to a biometrics system comprising one or more processors, computer storage memory having computer-executable instructions, surgically implantable devices, and wearables (e.g., an apparel item configured for an upper torso, an apparel item configured for a lower torso, a sock, a headband, other types of wearables, or one or more combinations thereof) having one or more biometric sensors (e.g., a heart rate sensor, a sweat sensor, a glucose sensor, other types of biometric sensors, or one or more combinations thereof) and one or more sensation devices (e.g., a plurality of visible light sources, a haptic feedback device, other types of sensation devices, or one or more combinations thereof). The wearables may also include one or more environmental sensors. The wearables emulate, transmogrify, or enhance one or more human senses using the one or more sensation devices based on biometric data or environmental data received.
Resumen de: US2025359762A1
Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.
Resumen de: WO2025244151A1
The present invention relates to a non-invasive glucose measurement device and method. To this end, the non-invasive glucose measurement device according to one embodiment of the present invention may comprise: a light irradiation unit which is positioned beneath an inner lower case disposed beneath an inserted finger, and which includes a first light-emitting element and a second light-emitting element for irradiating light toward the finger placed on the inner lower case; a light reception unit which is disposed on an inner upper case disposed on the finger, and which includes a first light-receiving element and a second light-receiving element for receiving the light irradiated from the light irradiation unit and transmitted through the finger; a motor unit including a first motor disposed at one side of the inner lower case and a second motor disposed at the other side of the inner lower case; a pressure sensor unit which is disposed beneath the inner lower case, and which includes a first pressure sensor and a second pressure sensor for measuring pressure applied by the finger; and a processor for measuring glucose by using the amount of light received through the light reception unit.
Resumen de: EP4653033A1
Provided is a safety insulin pen needle. The safety insulin pen needle includes a needle hub, a protective sleeve, a needle cap, and a limiting block. A fixed post protruding along with an injection needle is disposed on the needle hub. A snap-fit step is disposed on the surface of the fixed post. The injection needle is inserted through the protective sleeve. A spring is clamped between the protective sleeve and the needle hub such that the protective sleeve is axially movable relative to the needle hub to expose or cover a needle tip of the injection needle. A protruding edge is disposed on an outer wall of the protective sleeve. A first limiting step and a second limiting step are disposed on an inner wall of the protective sleeve along a direction in which the injection needle penetrates. The inner diameter of the second limiting step is smaller than the inner diameter of the first limiting step. The needle cap is fixedly assembled with the needle hub and encloses the protective sleeve within the needle cap. The needle cap is provided with a through-hole allowing the protective sleeve to extend out. The through-hole limits the protruding edge. The limiting block is located in an inner cavity of the protective sleeve and is sleeved on the injection needle. A first end of the limiting block is provided with a claw that engages with the snap-fit step, and a second end of the limiting block cooperates with the first limiting step or the second limiting step to stop the protec
Resumen de: ZA202305438B
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
Resumen de: AU2025223826A1
A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T
Resumen de: WO2025239063A1
This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects light that has been output by the light output unit and passed through a living body; a temporal phase difference calculation unit that, on the basis of the detection result of the light detection unit, calculates the temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration of the blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration of the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; a level of similarity estimation unit that estimates the level of waveform similarity between the oxygenated hemoglobin waveform and the deoxygenated hemoglobin waveform; and a reliability estimation unit that estimates the reliability of the calculated blood glucose level. The reliability estimation unit estimates that the reliability becomes smaller as the level of waveform similarity becomes smaller.
Resumen de: US2025352093A1
The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: US2025352095A1
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Nº publicación: US2025352726A1 20/11/2025
Solicitante:
DIABELOOP [FR]
DIABELOOP
Resumen de: US2025352726A1
A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).
BOPI
Sede Electrónica
